US Stock MarketDetailed Quotes
BCTX BriaCell Therapeutics
- 0.704
- +0.014+2.04%
Close Jul 23 16:00 ET
- 0.730
- +0.026+3.66%
Post 16:47 ET
12.87MMarket Cap-1902P/E (TTM)
0.730High0.601Low384.09KVolume0.690Open0.690Pre Close262.35KTurnover2.95%Turnover RatioLossP/E (Static)18.28MShares7.59052wk High-2.16P/B9.18MFloat Cap0.60152wk Low--Dividend TTM13.04MShs Float12.470Historical High--Div YieldTTM18.65%Amplitude0.601Historical Low0.683Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
BriaCell Therapeutics Stock Forum
3 MINUTES AGO, 7:56 AM EDT
VIA GLOBENEWSWIRE
BCTXBCTXW
SHARE
• Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3
• Significant reduction of "Eye-Bulging" metastatic breast cancer tumor was previously reported
• Heavily pre-treated patient had failed 8 prior regim...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, has recently reported significant positive clinical data for its lead product candidate, Bria-IMT™. This update has earned the company a reiterated "Buy" rating from HC Wainw...
No comment yet